The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 86 | 1.8x | 20.3x | Above average | |
Growth | 35 | -5.8% | 5.6% | Near average | |
Quality | 85 | 239.5% | 7.6% | Above average | |
Safety | 68 | 0.1x | 0.4x | Above average | |
Capital Return | 46 | 4.26% | 2.15% | Near average | |
Momentum | 25 | — | — | Below average | |
Sentiment | 58 | — | — | Near average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Novo Nordisk A/S is a global healthcare leader, primarily focused on innovating and developing advanced treatments for patients with diabetes, obesity, and other rare diseases. The company generates most of its revenue through the sale of innovative peptide-based medicines, particularly GLP-1 therapies that are experiencing unprecedented global demand. The company operates through two main business segments: U.S. operations and International Operations, aiming to expand patient access to its treatments, which currently serve approximately 46 million people worldwide.
During the fiscal year 2025, Novo Nordisk achieved total net sales of DKK 309.1 billion (compared to DKK 290.4 billion in 2024), gross profit of DKK 250.3 billion, and net income of DKK 102.4 billion, resulting in earnings per share (EPS) of 23.03. However, the company's gross margin decreased to 81% in 2025 compared to 84.7% in 2024, impacted by depreciation and amortization costs associated with the acquisition of three Catalent manufacturing sites, as well as exceptional restructuring costs of approximately DKK 8 billion.
Novo Nordisk stock currently trades at $42.96, which is significantly below the average analyst consensus price target of $49.5 (with estimates ranging from a low of $45 to a high of $54). According to analyst consensus, the current general recommendation for the stock is a Buy, indicating a positive valuation gap in favor of investors compared to the company's current market capitalization of $190.9 billion.
For 2026, the company expects adjusted sales growth and adjusted operating profit growth to range between a 5% decline and a 13% decline in constant exchange rates. This expected decline is mainly due to lower realized prices in the U.S. and the impacts of Most Favored Nation (MFN) agreements, in addition to the expiration of semaglutide patents in certain international markets. However, the results will benefit from the reversal of sales rebate provisions of USD 4.2 billion related to the 340B drug pricing program in the United States.
Oral Wegovy tablets were approved by the FDA on December 22, 2025, and were officially launched in the U.S. market on January 5, 2026. The launch was highly successful, with weekly prescriptions reaching approximately 50,000 for the week ending January 23, 2026, and nearly 45,000 of these prescriptions were through self-pay. This rate is more than double any previous anti-obesity drug launch in the United States.
The company recently announced positive Phase 3 results from the REIMAGINE 2 trial of CagriSema in type 2 diabetes, where it achieved a superior HbA1c reduction of 1.91 percentage points and weight loss of 14.2%. The company expects to announce results from the pivotal REIMAGINE 1 study in the first quarter of 2026, followed by discussions with regulatory authorities to determine the approval pathway for the drug. The company also plans to initiate new clinical trials for higher doses of CagriSema later this year.
Automated analysis for informational purposes only — not investment advice.
Novo Nordisk's Board of Directors proposes a final dividend of DKK 7.95 per share for 2025, bringing the total annual dividend to DKK 11.70, which is a 2.6% increase compared to the previous year and represents the 30th consecutive year of continuous increases. For 2026, the company expects to return cash flows to shareholders exceeding DKK 60 billion. In addition, the Board approved a new share buyback program of up to DKK 15 billion to be executed over the next 12 months.